
Eric Blount
Examiner (ID: 14763, Phone: (571)272-2973 , Office: P/2684 )
| Most Active Art Unit | 2684 |
| Art Unit(s) | 2684, 2612, 2636, 2685 |
| Total Applications | 1590 |
| Issued Applications | 1210 |
| Pending Applications | 89 |
| Abandoned Applications | 303 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20567492
[patent_doc_number] => 20260061410
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-03-05
[patent_title] => METHOD FOR MAKING A BENZIMIDAZOLE
[patent_app_type] => utility
[patent_app_number] => 19/383003
[patent_app_country] => US
[patent_app_date] => 2025-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7398
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19383003
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/383003 | METHOD FOR MAKING A BENZIMIDAZOLE | Nov 6, 2025 | Pending |
Array
(
[id] => 19862251
[patent_doc_number] => 20250101037
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
[patent_app_type] => utility
[patent_app_number] => 18/973867
[patent_app_country] => US
[patent_app_date] => 2024-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66487
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 283
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18973867
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/973867 | N/O-linked degrons and degronimers for protein degradation | Dec 8, 2024 | Issued |
Array
(
[id] => 19846713
[patent_doc_number] => 20250092064
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-20
[patent_title] => BENZOTRIAZOLE COMPOUND
[patent_app_type] => utility
[patent_app_number] => 18/927756
[patent_app_country] => US
[patent_app_date] => 2024-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 90809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18927756
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/927756 | Benzotriazole compound | Oct 24, 2024 | Issued |
Array
(
[id] => 19528078
[patent_doc_number] => 20240351980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => MASP-2 INHIBITORS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/679774
[patent_app_country] => US
[patent_app_date] => 2024-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18679774
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/679774 | MASP-2 INHIBITORS AND METHODS OF USE | May 30, 2024 | Pending |
Array
(
[id] => 19464013
[patent_doc_number] => 20240317682
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => MASP-2 INHIBITORS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/680563
[patent_app_country] => US
[patent_app_date] => 2024-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24188
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18680563
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/680563 | MASP-2 INHIBITORS AND METHODS OF USE | May 30, 2024 | Pending |
Array
(
[id] => 19658420
[patent_doc_number] => 20240425485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => PLINABULIN COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/671711
[patent_app_country] => US
[patent_app_date] => 2024-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11636
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18671711
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/671711 | PLINABULIN COMPOSITIONS | May 21, 2024 | Pending |
Array
(
[id] => 20414116
[patent_doc_number] => 12497386
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Estrogen receptor-modulating compounds
[patent_app_type] => utility
[patent_app_number] => 18/661960
[patent_app_country] => US
[patent_app_date] => 2024-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48064
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661960
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/661960 | Estrogen receptor-modulating compounds | May 12, 2024 | Issued |
Array
(
[id] => 19875860
[patent_doc_number] => 20250108117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-03
[patent_title] => C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/651408
[patent_app_country] => US
[patent_app_date] => 2024-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69870
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18651408
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/651408 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Apr 29, 2024 | Issued |
Array
(
[id] => 19593102
[patent_doc_number] => 12150920
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-26
[patent_title] => Topical pharmaceutical composition in the form of aqueous gel comprising at least amitriptyline
[patent_app_type] => utility
[patent_app_number] => 18/650932
[patent_app_country] => US
[patent_app_date] => 2024-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7379
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650932
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/650932 | Topical pharmaceutical composition in the form of aqueous gel comprising at least amitriptyline | Apr 29, 2024 | Issued |
Array
(
[id] => 19387760
[patent_doc_number] => 20240277630
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINE
[patent_app_type] => utility
[patent_app_number] => 18/650894
[patent_app_country] => US
[patent_app_date] => 2024-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7302
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650894
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/650894 | Topical pharmaceutical composition in the form of aqueous gel comprising at least amitriptyline | Apr 29, 2024 | Issued |
Array
(
[id] => 19745610
[patent_doc_number] => 20250034175
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/638558
[patent_app_country] => US
[patent_app_date] => 2024-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638558
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/638558 | Boronic acid derivatives and therapeutic uses thereof | Apr 16, 2024 | Issued |
Array
(
[id] => 19629643
[patent_doc_number] => 20240408092
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 18/624553
[patent_app_country] => US
[patent_app_date] => 2024-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624553
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/624553 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | Apr 1, 2024 | Pending |
Array
(
[id] => 19556327
[patent_doc_number] => 20240368119
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/621266
[patent_app_country] => US
[patent_app_date] => 2024-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51112
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621266
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/621266 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Mar 28, 2024 | Abandoned |
Array
(
[id] => 19432469
[patent_doc_number] => 20240300967
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => SYNTHETICALLY MODIFIABLE ION CHANNELS
[patent_app_type] => utility
[patent_app_number] => 18/611791
[patent_app_country] => US
[patent_app_date] => 2024-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611791
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/611791 | Synthetically modifiable ion channels | Mar 20, 2024 | Issued |
Array
(
[id] => 19464044
[patent_doc_number] => 20240317713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
[patent_app_type] => utility
[patent_app_number] => 18/607834
[patent_app_country] => US
[patent_app_date] => 2024-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45353
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -58
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18607834
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/607834 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Mar 17, 2024 | Abandoned |
Array
(
[id] => 19432460
[patent_doc_number] => 20240300958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => COMPOUNDS AND THE USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/599116
[patent_app_country] => US
[patent_app_date] => 2024-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4821
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599116
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/599116 | COMPOUNDS AND THE USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Mar 6, 2024 | Pending |
Array
(
[id] => 19614843
[patent_doc_number] => 20240400523
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => RAS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/592808
[patent_app_country] => US
[patent_app_date] => 2024-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 94812
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18592808
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/592808 | Ras inhibitors | Feb 29, 2024 | Issued |
Array
(
[id] => 20414118
[patent_doc_number] => 12497388
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same
[patent_app_type] => utility
[patent_app_number] => 18/590509
[patent_app_country] => US
[patent_app_date] => 2024-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 18
[patent_no_of_words] => 38371
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 319
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18590509
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/590509 | Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same | Feb 27, 2024 | Issued |
Array
(
[id] => 19922938
[patent_doc_number] => 12297209
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Benzodiazepine derivatives as RSV inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/584520
[patent_app_country] => US
[patent_app_date] => 2024-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70453
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584520
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/584520 | Benzodiazepine derivatives as RSV inhibitors | Feb 21, 2024 | Issued |
Array
(
[id] => 19745578
[patent_doc_number] => 20250034143
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/583293
[patent_app_country] => US
[patent_app_date] => 2024-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61423
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18583293
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/583293 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | Feb 20, 2024 | Pending |